Filing Flows › Immunome (IMNM) › Q1 2025
Immunome (IMNM) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Immunome (IMNM) reported revenue of $2.9M for the first quarter 2025 (Q1 2025), +184% from a year earlier and +7% from the quarter before.
Immunome, Q1 2025: revenue $2.9M (+184% year over year), net loss $41.6M, operating cash flow −$53.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.9M | +7% | +184% |
| Operating profit | −$44.6M | — | — |
| Net earnings | −$41.6M | — | — |
| Operating cash flow | −$53.1M | — | — |
What changed
Revenue was $2.9M in Q1 2025, up 184% year over year and up 7% from the previous quarter.
Operating costs exceeded revenue by $44.6M, an operating margin of -1525.5%. Total costs fell 64% while revenue rose 184%. The fastest-growing cost line was Research & development (+140%). The quarter ended with a net loss of $41.6M, narrower than the previous quarter's $80.2M loss.
Operating cash flow was −$53.1M. Non-cash charges added back $611K of depreciation and amortization and $5.7M of share-based compensation. Working capital and other items used $17.7M. Capital expenditures of $3.7M exceeded it, leaving free cash flow of −$56.7M.
Questions
What was Immunome's revenue in the first quarter 2025?
Immunome (IMNM) reported revenue of $2.9M for the first quarter 2025 (Q1 2025), +184% from a year earlier and +7% from the quarter before.
Source: Immunome 10-Q on SEC EDGAR.